Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TKT | P29401 | 17/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL3854523 | 0.99 | TKT (0.55) | TKTHSP90AA1 | |
| SCHEMBL13741511 | 0.78 | TKT (0.69) | TKTHSP90AA1 | |
| Hydrochloric Acid SCHEMBL21337 | 0.73 | LMNA (0.63) | TKTHSP90AA1 | |
| Hydrochloric Acid SCHEMBL29995247 | 0.73 | TKT (0.60) | TKTHSP90AA1 | |
| SCHEMBL249846 | 0.73 | ALDH1A1 (0.68) | — | |
| SCHEMBL29761314 | 0.72 | TKT (0.46) | TKTHSP90AA1 | |
| SCHEMBL13741392 | 0.72 | TKT (1.00) | TKTHSP90AA1 | |
| Thiamine Ion SCHEMBL29376635 | 0.71 | HSP90AA1 (0.87) | TKTHSP90AA1 | |
| Hydrochloric Acid SCHEMBL4102447 | 0.71 | TKT (0.98) | TKTHSP90AA1 | |
| Thiamine Ion SCHEMBL21751926 | 0.71 | HSP90AA1 (0.85) | TKTHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0808163-B1 | USE OF THIAZOLIUM COMPOUNDS FOR PREVENTING AND REVERSING THE FORMATION OF ADVANCED GLYCOSYLATION ENDPRODUCTS | ALTEON INC (US) | 2003-07-23 | — | — | EP | claimed |
| US-6440749-B1 | ADMINISTERING A THIAZOLE COMPOUND | ALTEON. INC. | 2002-08-27 | — | — | US | claimed |
| US-20090209554-A1 | Thiazoliums as transketolase inhibitors | ARRAY BIOPHARMA INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20020182165-A1 | Method and composition for rejuvenating hair, nails, tissues, cells and organs by ex-vivo or immersive treatment | FARRINGTON PHARMACEUTICALS, LLC | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209554-A1 | Thiazoliums as transketolase inhibitors | TKT, RRM2, TYMS | TKT 1/4885HSP90AA1 3622/4885 |
| US-20020182165-A1 | Method and composition for rejuvenating hair, nails, tissues, cells and organs by ex-vivo or immersive treatment | COL1A1, KRT18, COL2A1 | TKT 1088/4885HSP90AA1 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.